Pregabalin Dosing for Elderly Patients with Anxiety
Start pregabalin at 25-50 mg/day in elderly patients with anxiety, titrating slowly over weeks to a target dose of 150-300 mg/day divided into two doses, with careful monitoring for dose-dependent adverse effects that are particularly problematic in this population.
Initial Dosing Strategy
The elderly require substantially lower starting doses than standard adult recommendations. Begin with 25-50 mg/day rather than the FDA-labeled 150 mg/day starting dose for anxiety 1. This conservative approach is critical because older adults experience significantly more problematic side effects including somnolence, dizziness, mental clouding, balance disorders, and peripheral edema 1, 2.
Titration Protocol
- Week 1-2: Start at 25-50 mg/day (single dose or divided)
- Week 3-4: Increase to 75-150 mg/day in two divided doses if tolerated
- Week 5+: Titrate incrementally toward target of 150-300 mg/day in two divided doses
Dose escalation should be implemented at intervals long enough to allow monitoring of effects 1. The effective dose in older adults is typically lower than the 300-600 mg/day range seen in controlled studies of younger populations 1.
Target Maintenance Dose
The therapeutic range for anxiety in elderly patients is 150-300 mg/day divided into two doses. One open-label study in older patients with comorbid depression and generalized anxiety disorder successfully used 225 mg/day (reached over 4 weeks), demonstrating significant anxiety reduction by week 2-4 with minimal side effects 3. However, many elderly patients will respond to lower doses.
Critical Considerations for the Elderly
Renal Function Adjustment
Pregabalin is eliminated primarily by renal excretion, making dose adjustment essential in elderly patients with reduced creatinine clearance 4. Calculate creatinine clearance and adjust accordingly—patients with moderate renal impairment should start at the lowest doses (25 mg/day) 1.
Dose-Dependent Adverse Effects
A case report illustrates the severity of dose-related problems in the elderly: a 76-year-old developed balance disorder, weakness, peripheral edema, and constipation at 300 mg/day, which improved at 150 mg/day but recurred at 225 mg/day 2. The effective dose must be balanced against tolerability, as adverse effects can be dose-limiting 2.
Common Pitfalls to Avoid
- Do not use standard adult starting doses (150 mg/day)—this frequently causes intolerable side effects in elderly patients
- Do not escalate rapidly—older adults need slower titration with longer monitoring intervals
- Watch for falls risk—dizziness and balance disorders are particularly dangerous in this population 2
- Monitor for peripheral edema and constipation—these can develop even at moderate doses 2
Evidence Quality and Context
While pregabalin shows consistent efficacy for generalized anxiety disorder across multiple trials 5, 6, 7, the evidence specifically in elderly populations is limited. One controlled trial demonstrated effectiveness in patients ≥65 years 5, and the open-label study showed good response at 225 mg/day 3. However, recent concerns about long-term safety, dependence, and rising mortality rates have led to calls for re-evaluation of pregabalin's role in anxiety treatment 8.
A 2024 algorithm for GAD in older adults positions pregabalin/gabapentin as a third-line option, after SSRIs and SNRIs have been tried 9. This reflects both the limited elderly-specific evidence and safety concerns in this vulnerable population.
Discontinuation
When stopping pregabalin, taper gradually over a minimum of 1 week to avoid withdrawal symptoms 4. In elderly patients, consider even slower tapers given their increased sensitivity.